Profil contributes to the American Diabetes Association´s 73rd Scientific Sessions in Chicago, IL, June 21-25, 2013

• New insulin glargine U300 formulation evens and prolongs steady state PK and PD profiles during euglycemic clamp in patients with type 1 diabetes (T1DM)
  Jax T et al.

• Effects of a novel basal insulin, LY2605541, on hepatic glucose output and muscle glucose uptake: a physiology based simulation analysis
  Topp BG, Geiser JS, Soon DKW, Heise T, Michael MD, Jacober SJ, Beals JM, Sinha VP
• IDegAsp produces dose-proportional glucose-lowering effect in subjects with type 1 diabetes
  Heise T, Nosek L, Klein O, Coester HV, Roepstorff C, Svendsen AL, Haahr H
• IDegAsp shows distinct prandial and basal glucose-lowering effects at steady state in subjects with type 1 diabetes
  Heise T, Nosek L, Hastrup H, Chenji S, Klein O, Haahr H
• Euglycemic clamp profile of new insulin glargine U300 formulation in patients with type 1 diabetes (T1DM) is different from glargine U100
  Tillner J, Bergmann K, Teichert L, Dahmen R, Heise T, Becker RHA
• The dipeptidyl peptidase (DPP)-4 inhibitor linagliptin improves β-cell function and postprandial glucose in type 2 diabetes (T2D)
  Patel S, Heise T, Larbig M, Weber-Born S, Seck T, Hehnke U, Woerle HJ, Dugi K
• Metabolic effects and safety of two selective 11β-HSD1 inhibitors (RO5093151 (RO151) and RO5027838 (RO838) in metformin-treated patients with Type 2 Diabetes (T2D)
  Morrow L, Tim Heise, Hompesch M, Pieber TR, Häring HU, Christoph Kapitza, Abt M, Ramsauer M, Fürst-Recktenwald S
• A euglycemic clamp pilot study assessing the effects of the glucagon receptor antagonist LY2409021 on 24-hour insulin requirement in patients with T1DM
  Kazda CM, Garhyan P, Ding Y, Kelly RP, Hardy TA, Kapitza C
• Effect of canagliflozin (CANA) 300 mg on C-peptide clearance (CLCpep)
  Sha S, Polidori D, Heise T, Natarajan J, Artis E, Wang SS, Vaccaro N, Rothenberg P, Stirban A
  
  

Profil contributed to the 6th International Conference on Advanced Technologies and Treatment for Diabetes, Paris, France, February 27 – March 2, 2013

• Accuracy and reliability of current CGM systems; a direct comparison
  Luijf YM, DeVries JH, Mader JK, Doll W, Place J, Renard E, Bruttomesso D, Avogaro A, Benesch C, Heinemann L, AP@home Consortium
  
  

• Continuous blood glucose monitoring system using intravenous microdialysis and glucose sensing
  Schaller-Ammann R, Greiner H, Huber A, O'Connell M, Krejci J, Porro G, Korsatko S, Gurban J, Deller S, Brunner M, Berghofer A, Priedl J, Zijlstra E, Heise T, Pieber TR, Schaupp L
  
  

Profil contributed to the Congress of the Romanian Diabetes Federation, Cluj-Napoca, Romania, November 08-10, 2012

• Non-invasive methods for the assessment of vascular function
  Stirban AO
  
  
• Biomarkers and surrogate endpoints in clinical diabetes researach
  Schliess F
  
  
• Liver first? The liver in diabetes and cardiovascular disease
  Schliess F
  
  

Profil contributed to the 12th Diabetes Technology Meeting, Bethesda, MD, USA, November 08-10, 2012

• Biosimilar insulins
  Heinemann L
  
  
• Ultra-long-acting insulins: do we need them?
  Heise T
  
  

• ClampArt: improving the quality of glucose clamps with a novel, conformité européenne-marked device
  Benesch C, Haensler J, Heise T
  
  
• Accuracy and reliability of current continuous glucose monitoring systems: a direct comparison
  Luijf YM, DeVries JH, Mader JK, Doll W, Place J, Renard E, Bruttomesso D, Filippi A, Benesch C, Heinemann L
  
  
• Improved performance of continuous blood glucose monitoring using intravenous microdialysis and the enhanced ionic reference technique
  Schaller-Ammann R, Korsatko S, Binder B, O’Connell M, Krejci J, Porro G, Zijlstra E, Heise T, Pieber TR, Schaupp L
  
  
• Performance of a microdialysis-based continuous glucose monitoring system for hospital care
  Zijlstra E, Heise T, Künnecke W
  
  

Profil contributed to the American Society of Nephrology (ASN) Kidney Week, San Diego, CA, USA October 30 – November 04, 2012

• Validation of a novel method to determine the renal threshold for glucose in untreated and canagliflozin-treated subjects with type 2 diabetes
  Polidori D, Sha S, Rothenberg PS, Plum-Mörschel L, Heise T
  
  

Profil contributed to the 15th Annual CDA/CSEM Professional Conference and Annual Meeting Vancouver, BC, Canada October 10-13, 2012

• Insulin degludec 200 U/ml is ultra-long-acting and has a flat and stable glucose-lowering effect
  Heise T, Nosek L, Hövelmann U, Bøttcher SG, Hastrup-Nielsen H, Boras D, Haahr HL
  
  

• Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region
  Nosek L, Coester HV, Thomsen HF, Roepstorff C, Haahr HL, Sin R, Heise T
  
  
• Steady state is reached within two to three days of once-daily administration of ultra-long-acting insulin degludec
  Heise T, Nosek L, Coester HV, Roepstorff C, Segel S, Lassota N, Boras D, Haahr HL
  
  

Profil contributed to the EASD 48th Annual Meeting in Berlin, Germany, October 1-5, 2012
EASD 2012 Contributions Profil Germany

Profil contributed to the 8th IFAC Symposium on Biological and Medical Systems, Budapest, Hungary, August 29-31, 2012

• AP@home: An European project to bring the Artificial Pancreas home. 8th BMS
  Heinemann L
  
  

Profil contributed to the Symposium on Practical ways to Achieve Targets in Diabetes Care, Keystone, CO, USA, July 12 – 15, 2012

• Need for better insulins and biosimilars
  Heinemann L
  
  
• Strengths, weakness and performance issues with SMBG
  Heinemann L
  
  

Profil contributed to the American Diabetes Association´s 72th Scientific Sessions in Philadelphia, PA, June 08-12, 2012
ADA 2012 Contributions Profil Germany

Profil contributed to the Joint Symposium of the Collaborative Research Centers SFB 575 “Experimental Hepatology” and SFB 974 “Communication and Systems Relevance in Liver Damage and Regeneration”, April 20 - 21, 2012, Heinrich-Heine-University Düsseldorf, Germany Program.pdf

• Cell volume dependence of hormone and cytokine signaling
  Schliess F
  
  

Profil contributed to the 33rd Annual International Gravitational Physiology Meeting, Aberdeen, UK, June 18-22, 2012

• Acid-base balance and the musculoskeletal system
  Heer M
  
  
• Energy expenditure and muscle metabolism during medium-term bed rest
  Boschmann M, Frings-Meuthen P, Klug L, Parreidt N, Mähler A, Bühlmeier J, Heer M
  
  
• Effects of potassium bicarbonate supplementation on calcium and bone metabolism during 21-days of bed rest
  Frings-Meuthen P, Boehme G, Rittweger J, Heer M
  
  

Profil contributed to the “Jahrestagung der Deutschen Diabetes Gesellschaft” in Stuttgart, Germany, June 16-19, 2012

Session: Freie Vorträge VIII: Neue Studien zu Medikamenten in der Diabetestherapie
Chairmen: Tim Heise, Michael Nauck

• Artifizielles Pankreas, Stand der Entwicklung. Symposium: Update: Diabetes-Technologie
  Heinemann L
  
  
• Diabetes-Technologie: Nur CGM and CSII? Symposium: Diabetes-Technologie in der Realität
  Heinemann L
  
  
• Kontinuierliches Glukosemonitoring – in Studien und in der Praxis
  Heinemann L
  
  
• Das neue ultra-langwirksame Basalinsulin Insulin Degludec: flaches Wirkprofil mit gleichmäßiger Verteilung des blutzuckersenkenden Effekts bei Typ 2 Diabetes
  Heise T, Nosek L, Wilhelm B
  
  
• Das ultra-langwirksame Basalinsulin Insulin degludec: Zweifach längere Halbwertzeit und flacheres pharmakokinetisches Profil als Insulin Glargin
  Heise T, Hövelmann U, Nosek L, Wilhelm B
  
  
  

Profil contributed to the Grand Rounds of the Diabetes Center, Ann Arbor, MI, USA, May 15, 2012

• Postprandial endothelial function in diabetes: between ecstasy and agony
  Stirban A
  
  

Profil contributed to the conference on Experimental Biology, San Diego, CA, USA, April 21–25, 2012

• Urinary acid excretion can predict changes in bone metabolism during space flight
  Zwart SR, Heer M, Smith SM
  
  

• High protein intake improves insulin sensitivity but exacerbates bone resorption in immobility
  Heer M, Smith SM, Frings-Meuthen P, Zwart SR, Baecker N
  
  

Profil contributed to the Society for Endocrinology BES 2012, Harrogate, UK, March 19-22, 2012

• Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile compared with insulin glargine.
  Heise T, <>Hövelmann U, Nosek L, Bøttcher SG, Granhall C, Haahr H
  
  

Profil contributed to the 2nd Italian Diabetes Technology Meeting, Turin, Italy, March 03, 2012

Profil contributed to the 5th International Conference on Advanced Technologies & Treatments for Diabetes, Barcelona, Spain, February 08 - 11, 2012

AP@home: halftime of a European artificial pancreas project.
Heinemann L

• Diabetes technologies – regulatory topics that need more focus in Europe: The German experience
  Benesch C
  
  
• New ways of insulin delivery
  Heinemann L
  
  
• Continuous glucose monitoring: reimbursement across Europe
  Heinemann L
  
  
• Continuous blood glucose monitoring by combining intravenous microdialysis and ionic reference technique.
  Schaupp L, Schaller R, Huber A, Korsatko S, Deller S,> Brunner M, Berghofer A, O’Connell, Zijlstra E, Heise T, Pieber TR
  
  

• AP@home Consortium Continuous glucose monitoring accuracy assessed at home is seemingly better than when assessed at the clinical research centre.
  Luijf Y, Avogaro A, Benesch C, Bruttomesso D, Cobelli C, Ellmerer M, Heinemann L, Mader J, DeVries JH
  
  
• Intradermal pre-prandial delivery of insulin lispro provides more rapid onset and improved blood glucose excursions compared to subcutaneous delivery
  McVey E, Sutter DE, Judge K, Dellweg S, Clair J, Kapitza C, Hirsch L, Rebrin K, Pettis RJ
  
  
• Continuous glucose monitoring (CGM): A new method using on-line microdialysis in blood
  Zijlstra E, Hartlep M, Heise T, Künnecke W
  
  

Profil contributed to the 47th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Lisbon, Portugal, September 12-16, 2011

Profil contributed to the American Diabetes Association´s 71th Scientific Sessions in San Diego, CA, June 24-28, 2011

Profil contributed to the Meeting of the Diabetes and Nutrition Study Group in Rome, Italy, June 30 – July 2, 2011

Profil contributed to the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden, September 21-24, 2010

Profil contributed to the American Diabetes Association´s 70th Scientific Sessions in Orlando, FL, June 25-29, 2010